Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2007

View Archived Issues

Human fibroblast growth factor safe, active in coronary artery disease patients

Prolonged renal effects seen with AlbuBNP in dogs

Sitaxsentan assessed as a possible treatment for Eisenmenger's syndrome

Combination therapy with lapaquistat and atorvastatin improves hypercholesterolemia

Bioponic launches Curemisinin for the treatment of malaria in Africa

Preclinical profile of Merck & Co.'s novel NR2B-selective NMDA antagonist

Neuroprotection by small-molecule Hedgehog agonist in an in vitro model of ischemia

Provectus begins phase II clinical trial for psoriasis

VaxGen and Raven announce definitive merger agreement

Novel antiatherosclerotic agents emerge from Merck & Co. R&D

Final positive results announced from phase II GHRH trial

New data for mipomersen in routine high cholesterol patients

MedImmune and Infinity initiate phase II clinical trial of IPI-504 for prostate cancer

Novexel initiates phase II clinical trial of NXL-103 for community-acquired pneumonia

Karo Bio initiates phase IIb clinical study of KB-2115 for dyslipidemia

Avax initiates phase III clinical study of M-Vax in metastatic melanoma

AEterna Zentaris completes patient enrollment in phase II trial of perifosine

Northwestern University initiates enrollment in phase IIb study of Nexavar

New agents for treating neurological disorders disclosed in recent patent literature

Ceregene completes enrollment in phase II clinical trial of CERE-120 for Parkinson's disease

Amylin reports positive results from phase IIa study of pramlintide and metreleptin

The Juvenile Diabetes Research Foundation and Lilly fund research in diabetes biomarkers

CHMP gives positive approval for Avastin for the first-line treatment of renal cell carcinoma

Pfizer acquires Coley Pharmaceutical Group

CHMP gives positive opinion for Abbott's Humira in treatment of moderate to severe plaque psoriasis

FDA approves Seroquel XR for maintenance treatment of schizophrenia

Tibotec initiates phase II trial of telaprevir in treatment-naive chronic hepatitis C patients

Novel small-molecule compound appears to extend L-DOPA antiparkinsonian effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.